Objective: To examine the relationship between C-reactive protein (CRP), adiposity and other metabolic abnormalities in an Aboriginal community in Northern Australia. Design: Cross-sectional analysis of data obtained between 2001 and 2003 from 379 Aboriginal people residing in a geographically isolated community. Results: Mean (95% CI) CRP in women and men was 4.06 cholesterol (3.53, 4.66) mg/l and 3.42 (2.94, 3.97) mg/l, respectively (P ¼ NS). The prevalence of the metabolic syndrome (US National Education program (NCEP) definition) was significantly higher for women than men (41 vs 18%, w 2 ¼ 20.94, Po0.001). C-reactive protein correlated strongly with adiposity in women (waist circumference, waist to hip ratio and body mass index; rX0.514, Po0.01) but much less strongly in men (rp0.221, Po0.05). In a multivariate stepwise linear regression model, waist circumference was the strongest independent predictor explaining 35% of CRP concentration variance in women, but only 5.4% in men (WHR). Incremental increases in CRP concentration across four BMI categories were significant in women (P linear trend o0.001) but not in men. Conclusions: High CRP levels in the surveyed population are consistent with the high prevalence of vascular disease morbidity and mortality in Aboriginal Australians. The relationship of CRP with increasing body fat was strong and consistent in women but not in men. Prospective studies are needed to elucidate the role of CRP (if any) as a predictive marker for cardiovascular events in this high-risk population.
Introduction
High premature mortality from cardiovascular disease (CVD), predominantly ischaemic heart disease, is an important contributor to the 20 years shorter median life expectancy in Indigenous Australians relative to nonIndigenous Australians. 1, 2 Inflammation is recognised as a central feature of atherogenesis and plays a critical role in destabilisation of the fibrous cap, predisposing to plaque rupture that triggers most episodes of coronary thrombosis. 3 An acute phase reactant, the pentraxin C-reactive protein (CRP) is mainly produced in the liver and is upregulated by tumour necrosis factor a, interleukin (IL)-1b and IL-6 in response to infection or injury, 4 thus making it a suitable systemic marker of inflammation. C-reactive protein has been shown to be positively associated with age, body mass index (BMI), smoking, diabetes mellitus and obesity, 5, 6 and it has been proposed that relatively modest elevations of circulating CRP concentrations identify people at high risk of coronary events. [6] [7] [8] Furthermore, it has been proposed that CRP enhances the capacity of the metabolic syndrome to identify people at risk of future cardiovascular events. 9, 10 The American Heart Association (AHA) has recently recommended CRP measurement for evaluation of CVD risk with serum levels of 1.0 to 3.0 mg/l being associated with moderate CVD risk and levels above 3.0 mg/l associated with high risk. 11 Chronic inflammation may be an important contributor to the excess CVD risk experienced by Aboriginal people in Australia. 12 In the current study, the relationship between CRP, adiposity and other metabolic abnormalities in Aboriginal people from an isolated coastal community in the Northern Territory was examined.
Materials and methods
Participants and screening procedures Risk factor screening was carried out between 2001 and 2003 as part of evaluation of a community-directed intervention program in an isolated coastal community in the northeast of Arnhem Land. Screening was offered to all residents aged 15 years and older. Age was determined by self-report and confirmed from clinical records. Anthropometric measurements included weight, height, waist and hip circumferences using standard techniques. 13 The mean of three consecutive blood pressure measurements was taken with an automated Dinamap (Critikon, USA) after the participant had been sitting for 5 min.
Sample handling
Venipuncture was performed on the medial cubital vein after an overnight fast and blood was drawn directly into evacuated tubes using aseptic precautions. Subjects provided a urine sample into a standard urine collection container. All samples were kept in insulated containers packed with ice blocks and processed after a maximum time of 4 h. Supernatant was subsequently stored in a liquid-nitrogen 'Biological Shipper' (CryoPak Series, Taylor-Wharton, AL, USA) until arrival at the laboratory and subsequently stored at À801C until analysis.
Biochemical analyses
Plasma glucose and lipids were measured by standard automated colorimetric methods using commercial reagents, except for low density lipoprotein cholesterol (LDL-C) which was calculated using the Friedewald equation: LDL-C ¼ total cholesterol -high density lipoprotein cholesterol (HDL-C) -(triglycerides in mM/2.17); Glycated haemoglobin (HbA 1c ) was assayed using cation exchange HPLC on a Pharmacia MonoS column; plasma insulin was measured by radioimmunoassay; plasma homocysteine was assayed by automated fluorescence polarisation immunoassay on an Abbott IMx s autoanalyzer; serum CRP was measured with high sensitivity commercial assay (BN-II Nephelometer; Dade Behring Diagnostics, Lane Cove, NSW; intra and inter assay CVs of 1.9 and 4.4%, respectively, with a lower limit of detection of 0.175 mg/l); Urinary albumin was quantified by immunonephelometry using the Beckman Array method, and urine creatinine by the kinetic Jaffe reaction on the Hitachi 917 analyser. All routine biochemical analyses were performed by a NATA accredited diagnostic laboratory (SouthPath Flinders Medical Centre, SA Australia), and CRP was measured in our research laboratory.
Classification of conditions and categories
The criteria for the metabolic syndrome were those of the US National Cholesterol Education Program (NCEP): three or more of: waist circumference X88.0 cm for women and X102.0 cm for men; fasting plasma triglycerides X1.7 mmol/ l; fasting HDL-C o1.29 mmol/l for women and o1.03 mmol/ l for men; systolic/diastolic blood pressure X130/X85 mm Hg, and; fasting plasma glucose (FPG) X6.1 mmol/l. 14 Albuminuria was defined as urinary albumin to creatinine ratio (ACR) X3.4 mg/mmol. 15 Smoking status (yes/no) was established. The AHA definition for three relative risk categories of CRP was used: o1.0 mg/l, 1.0 to 3.0 mg/l and 43.0 mg/l. 11 The proportion of samples with clinically raised CRP concentration (410.0 mg/l) was also reported. Analysis includes all CRP data as no bimodal distribution of CRP was present in this population, therefore the use of an arbitrary cutoff based on non-Aboriginal groups was not justified. When analyses were repeated excluding participants with CRP410 mg/l, the major findings were not significantly altered. 
Statistical analyses

Results
Two hundred and four women and 175 men were included in this analysis and the age distribution of the total sample Table 1 presents the clinical characteristics of the survey sample: women had higher BMI and waist circumference than men but similar WHR. Women also had higher insulin levels but lower homocysteine, HDL-C and blood pressure. The range of CRP values in women and men was 0.47-30.0 mg/l and 0.38-69.5 mg/l respectively, and mean CRP was very high in both sexes. The proportions of those in different concentration categories are shown in Figure 1 . Over 50% of the population were categorised into the high CRP risk group and nearly 20% had CRP conventionally used to identify acute sepsis. C-reactive protein levels remained high after exclusion of the 44 women and 29 men with CRP concentration 410 mg/l: mean (95% CI) CRP was 2.87 (2.52, 3.27) mg/l and 2.53 (2.20, 2.90) mg/l respectively for women and men (P ¼ 0.188). Smoking was highly prevalent in both sexes, however, there was no statistical difference between smokers and nonsmokers (P women ¼ 0.774, P men ¼ 0.058). The prevalence of the metabolic syndrome according to NCEP criteria was much higher in women than in men (41 vs Bivariate and partial correlations of CRP with clinically relevant variables (including those making up the metabolic syndrome) confirmed strong and statistically significant relationships between CRP and anthropometric variables in women but much less so in men. After controlling for WHR or BMI significant relationships with CRP were only found for total and LDL-C (both Po0.05) for women but not for men (both P40.05; data not shown). Figure 2 presents mean (s.e.m.) CRP concentration across four conventional BMI categories in men and women. While mean levels of CRP were similar in men and women, the relationships with BMI were very different: CRP rose sharply with increasing BMI in women (P linear trend o0.001), but not in men (P linear trend ¼ 0.198). Lean women had lower CRP concentration than lean men (P ¼ 0.012), but in the overweight and obese BMI ranges women had higher CRP concentrations than men (Po0.05). CRP concentration in the so-called 'healthy BMI' range was not significantly different between the sexes (P ¼ 0.756).
In a multivariate stepwise linear regression model presented in Table 2 , waist circumference was the major independent predictor explaining 35% of the variance in CRP concentration in women, however none of the variables explained the variance in CRP to any meaningful extent in 
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.4%). Factor analysis confirmed a clustering
of CRP with adiposity in women (factor loading 40.6 for relevant components) but not in men (data not shown).
Discussion
The most striking observations in this study were the high circulating levels of CRP in this population, the strong relationship of CRP with increasing BMI in women but not in men, and the very high prevalence of central obesity and metabolic syndrome in women. Based on the AHA risk model in relation to CRP (CRP 43.0 vs CRP o1.0 mg/l 11 ), over 50% of people in the present survey sample were at twofold increased cardiovascular risk, an outcome that is consistent with high prevalence of premature cardiovascular mortality in Aboriginal Australians.
High circulating CRP levels have been reported previously in other Australian Aboriginal populations. 12, 17 High prevalence of infectious diseases has also been previously reported, [18] [19] [20] [21] and are known to increase CRP production by the liver. This is likely to be related to a constellation of factors secondary to poor quality housing and overcrowded living conditions, and poor nutrition. Consistent with this, a study in a neighbouring Indigenous community reported that CRP concentrations were significantly associated with IgG seropositivity to Helicobacter-pylori, Chlamydia-pneumoniae and cytomegalovirus. 17 However, exclusion of those with CRP410.0 mg/l, often considered to be associated with infection, did not significantly alter statistical relationships of CRP to anthropometric and other variables and consequent conclusions of our study. Psychosocial factors such as depression, anxiety, social isolation and chronic life stress have been shown to be associated with an acceleration of carotid atherosclerosis, probably via hyperresponsivity of the hypothalamic-pituitary-adrenal axis. A recent review by Black 22 suggested that the detrimental impact of psychosocial stress on cardiovascular health is at least partly mediated by inflammatory responses. This conclusion is supported by a Finnish study reporting an inverse association of CRP and other systemic inflammatory markers with socioeconomic status in middleaged men. 23 Given the high levels of CVD among Indigenous Australians, we suggest that psychosocial stress may be an important mediator of increased circulating CRP levels, thereby promoting the progression of chronic diseases, such as vascular disease and diabetes. 24 Poor nutritional status in remote Aboriginal communities is well established. [25] [26] [27] In this context, we have reported inverse associations of CRP and activity of the HDL-C associated anti-oxidant enzyme paraoxonase-1 with plasma diet-derived antioxidants in a Western Australian Aboriginal population. 12, 28 In addition to its recognised role in reverse cholesterol transport, HDL-C has antioxidant, antithrombotic and anti-inflammatory actions. 29, 30 Low levels of paraoxonase-1 activity, which may reflect reduced capacity to hydrolyse lipid peroxides, have been linked to coronary heart disease (CHD). 31 We have previously reported increases in paraoxonase-1 activity in Indigenous Australians with improved dietary quality. 28 Low levels of atheroprotective HDL-C and low fruit and vegetable intake, consistent with high homocysteine levels, may amplify poor antioxidant defence and a proinflammatory state, thus promoting atherosclerosis and associated diseases. One of the most interesting observations in this study was that CRP concentrations were strongly related to increasing BMI in women, but not in men. To the best of our knowledge, this observation is the first to be described for Australian Aboriginal people, but has been described for other populations 32, 33 and attributed, at least in part, to differences in the proportion of body fat (higher in women for a given BMI). However, this does not explain why lean men (BMI o20 kg/m 2 ) would have higher CRP levels than lean women. Alternative explanations need to be sought. CRP may well be differentially linked to CVD in women and men. In support of this possibility, the Framingham Heart Study reported a much stronger association of CRP with atherosclerosis in women than in men, after adjusting for potential confounders. 34 There is a paucity of literature which could help explain this phenomenon. One possibility is that it is related to the sex hormone profile. It is well established that centrally obese women have a relatively high free testosterone index which increases with weight gain. 35 In support of a role for androgenicity is a recent study reporting that several endogenous sex hormones influence levels of inflammatory markers (including CRP and fibrinogen) in postmenopausal women, and that this relationship was related to BMI. 36 It is important to note in this context that Australian Aboriginal women characteristically exhibit a pattern of C-reactive protein and adiposity in aboriginal Australians T Shemesh et al abdominal fat deposition when they gain weight. 37 The low levels of HDL-C and high insulin and triglyceride concentrations in women in this study confirm that this is associated with an unusually adverse metabolic profile. However, in the absence of longitudinal data it is not possible to conclude that increases in CRP levels in association with increasing central fat deposition are a strong marker of CVD risk in Aboriginal women in particular. Furthermore, as high CRP levels were observed across BMI strata for both sexes, even in the lean BMI category, other underlying mechanisms in addition to adiposity are likely to modulate CRP and associated CVD risk, particularly in men. Our finding of overall high prevalence of adverse metabolic profile is consistent with other studies on Australian Indigenous populations. [38] [39] [40] [41] A recent review by Ridker et al. suggested that the inclusion of CRP as a component of the metabolic syndrome is timely as it enhances the prognostic properties of the metabolic syndrome as a predictor of CHD events. In contrast, another report suggested that the value of additional information from CRP has been exaggerated by a positive report bias prior to year 2000, confounding the true value of this marker. 42 These authors concluded that CRP was a less important predictor of CHD than cholesterol.
The results of the present study suggest that this conclusion may not be generalisable across different population groups. Cholesterol levels were not elevated in this study population, however, their relationship to CRP was independent of measures of adiposity in women. Additionally, the most striking lipid abnormality in this population is the dyslipidemia associated with insulin resistance and diabetes (elevated triglycerides and low HDL-C). Indeed, these data are consistent with high CVD mortality in the surveyed population, but without longitudinal data we are unable to estimate their predictive statistical power.
The main limitations of this study are its cross-sectional nature and the lack of information on the presence of infections and medications taken at the time of screening.
In conclusion, CRP levels in the surveyed sample of Indigenous Australians are very high and consistent with high levels of CVD morbidity and mortality in Aboriginal peoples. The relationship of CRP with surrogate markers of body fat is strong and consistent in women but not in men. A focus on conventional risk factors such as cholesterol and blood pressure may not be sufficient given the very high inflammatory load in this population. Prospective studies are needed to elucidate the role of CRP as a predictive marker for cardiovascular events in this population.
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